💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Lorazepam

CHEMBL580 Phase 4 已批准 Small molecule
Half-Life
10-20 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
321.2 g/mol
LogP
2.4
Phase
4

A benzodiazepine used to treat anxiety disorders, status epilepticus, insomnia, and agitation, and studied as a sedative in critically ill patients. It enhances GABA activity in the brain, producing calming, sedating, and anticonvulsant effects.

分子量

321.1580 g/mol

LogP

2.40

TPSA

61.70 Ų

Lipinski 五规则

符合

治疗领域

Pancreatic Cancer Bladder Cancer Benign Prostatic Hyperplasia Glaucoma Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Lymphoma Hypertension Major Depressive Disorder Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer Leukemia

药物分类

N — N - Nervous System

作用机制

Intermediate-acting benzodiazepine enhancing GABA-A receptor chloride conductance.

Pharmacokinetics (PK)

Half-Life 10-20 hours

Pharmacodynamics (PD)

机制

Intermediate-acting benzodiazepine enhancing GABA-A receptor chloride conductance.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O

                

                

                
                

                    
InChI

                    
InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H10Cl2N2O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 3

                    

                    
                    

                        
可旋转键数

                        
1

                    

                    
                    
                    

                        
重原子数

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
A benzodiazepine used to treat anxiety disorders, status epilepticus, insomnia, and agitation, and studied as a sedative in critically ill patients. It enhances GABA activity in the brain, producing calming, sedating, and anticonvulsant effects.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Intermediate-acting benzodiazepine enhancing GABA-A receptor chloride conductance.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Lorazepam: Half-life: 10-20 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Lorazepam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL580.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3958.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.